Research programme: obesity therapy - Nanodesign
Alternative Names: Obesity therapy research programme - NanodesignLatest Information Update: 20 Nov 2002
At a glance
- Originator Nanodesign (CEASED); SignalGene [CEASED]
- Class
- Mechanism of Action ERRalpha estrogen-related receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 20 Nov 2002 Discontinued - Preclinical for Obesity in Canada (unspecified route)
- 21 May 2001 This programme is available for licensing or co-development (http://www.nanodesign.com)
- 16 Jan 2001 Preclinical development for Obesity in Canada (Unknown route)